Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. [electronic resource]
Producer: 20191220Description: 3282-3291 p. digitalISSN:- 1557-3265
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents, Immunological -- administration & dosage
- B7-H1 Antigen -- genetics
- Biomarkers, Tumor
- Biopsy
- Computational Biology
- Drug Resistance, Neoplasm
- Female
- Gene Rearrangement
- HLA Antigens -- immunology
- Humans
- Molecular Targeted Therapy
- Mutation
- Ovarian Neoplasms -- diagnosis
- Positron Emission Tomography Computed Tomography
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Receptors, Cell Surface -- genetics
- Retreatment
- T-Lymphocytes -- drug effects
- Treatment Outcome
- Exome Sequencing
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.